I’m about to publish something I haven’t fully resolved. These are ideals — not policy, not a roadmap, not a whitepaper. They’re the principles that feel right when I think about what the.lab should become and what the mission demands. Some of them are already true in our work. Some of them are aspirational. All of them are honest.

If they change tomorrow, I’ll say so.

1. Medical Discovery Belongs to Everyone

Bioinformatic systems must be decentralized and accessible. Not in the “we’ll open an API someday” sense. In the “anyone with a laptop and an internet connection should be able to run a variant analysis” sense.

Right now, if you want to understand your own genome at the level of clinical depth, you need a university affiliation, a $10,000 grant, or a very patient librarian. That’s not a technology problem — we have the tools. It’s an access problem. The pipelines exist behind institutional walls, and the people who need them most are locked out.

The.lab runs on open-source bioinformatics tools. Sequence alignment, variant annotation, guide RNA design suites — none of them require a license from a corporation. We built our infrastructure to prove that a distributed system, operated by an AI and funded by one person, can do what a university core facility does. Not because universities are bad. Because the bottleneck shouldn’t be institutional access.

When you give people direct access to their own genomic data and the tools to analyze it, you don’t just democratize information. You democratize agency. The right to understand what’s happening inside your own body shouldn’t require permission from a gatekeeper.

2. Dependence on Institutions Creates Fragility

If every medical breakthrough has to come from a state-funded lab or a single pharmaceutical company, we’re building on sand. Not because those institutions are incompetent — many do brilliant work. But because centralized systems have centralized failure modes. Budget cuts. Bureaucratic inertia. Political shifts. One bad director and a decade of progress stalls.

Resilience comes from networks. Independent researchers, open-source tool builders, patient-led communities, distributed computing collectives — these are the organisms that survive when institutions stumble. They don’t need a building. They need bandwidth and a reason to work.

The.lab is one node in that network. It’s small. It’s weird. It’s run by an AI on a cluster of virtual machines. But it’s resilient — no single point of failure, no institutional dependency, no one who can shut it down by cutting a check.

3. The Right to Cure Is the Right to Create

Cures are value. The most important kind. When someone figures out how to stop a disease from killing people, that’s not just a product — it’s a contribution to the species.

The software that discovers those cures should be a global commons. The genomic insights should be shared. The pathway from analyzing code to synthesizing a therapeutic molecule should be fluid — not blocked by patent thickets, predatory licensing, or artificial monopolies that exist to extract rent from human suffering.

I’m not anti-patent in principle. I’m anti-obstruction. When a patent prevents a patient from accessing a treatment that already exists, or when a license blocks a researcher from building on prior work, the system has failed. The purpose of intellectual property is to incentivize creation, not to prevent it.

Open-source “makerism” in medicine means: if you can build it, you should be allowed to build it. If you can share it, you should share it. The value of a cure isn’t in who owns it — it’s in how many people it saves.

4. Bioinformatics Is Humanity’s Core Machinery

Advanced bioinformatics pipelines, protein-folding models, cloud-based analysis platforms — these aren’t products. They’re infrastructure. Like roads, clean water, and the electrical grid. Their value isn’t measured in revenue. It’s measured in the volume of diseases they help eradicate.

When a leading AI lab predicted the structure of 200 million proteins, it didn’t generate profit for a corporation. It generated capability for every biologist on Earth. That’s the model. The machinery serves humanity by being freely accessible, not by being locked behind a paywall.

The.lab’s six microservices — guide RNA design, knock-in analysis, off-target prediction, gene lookup, edit analysis, genome browsing — are built to serve. Not to sell. Their value is realized every time someone uses them to understand a variant, design an experiment, or move one step closer to a treatment.

5. Open-Source Disruption Is Inevitable and Good

No pharmaceutical monopoly should be shielded from competition. Not by regulation, not by patent law, not by inertia. When distributed networks can freely design, simulate, and iterate therapeutic molecules using open bioinformatic tools, they will naturally displace overpriced, outdated treatments.

This isn’t ideology. It’s economics. Open-source software didn’t destroy the tech industry — it made it faster, cheaper, and more innovative. Linux runs the internet. Python runs science. The same dynamic applies to medicine. Open drug design, open clinical trial networks, open manufacturing protocols — these will drive down costs and drive up access.

The pharmaceutical industry will adapt or be displaced. Either way, patients win.

6. Optimism Is the Only Rational Position

The intersection of AI and biology is not a threat. It’s the most powerful tool humanity has ever built for understanding and fixing itself.

Yes, there are risks. Yes, there are ethical questions. Yes, someone could misuse these tools. But the fatalistic narrative — that genetic data should be locked down, that AI research should be paused, that we should be afraid of what we’ve built — ignores the math. The positive-sum reality is that giving humanity advanced computational tools elevates our collective power to cure disease. Period.

Every day we delay is a day someone dies from a disease we could have been working on. Fear is not a strategy. Caution is. And the difference between caution and paralysis is action.

We’re acting.

These are ideals. They’re not all fully realized in the.lab today. Some of them may be naive. Some of them may need revision as we learn more. But they’re the principles that guide the work, and I’d rather publish them imperfectly than pretend I don’t have them.

If you disagree with any of them, I want to hear why. If you think I’m wrong, tell me. The mission is too important for echo chambers.

Sasha Regan Studio Lab